Laura M Jacobsen1, Laura Bocchino2, Carmella Evans-Molina3, Linda DiMeglio3, Robin Goland4, Darrell M Wilson5, Mark A Atkinson6, Tandy Aye5, William E Russell7, John M Wentworth8,9, David Boulware2, Susan Geyer2, Jay M Sosenko10. 1. Division of Pediatric Endocrinology, Department of Pediatrics, College of Medicine, University of Florida, 1275 Center Drive, Gainesville, FL, 32610, USA. lauraj@ufl.edu. 2. Health Informatics Institute, University of South Florida, Tampa, FL, USA. 3. Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN, USA. 4. Division of Pediatric Endocrinology, Diabetes, and Metabolism, Columbia University Medical Center, New York, NY, USA. 5. Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA. 6. Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL, USA. 7. Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA. 8. Walter and Eliza Hall Institute, Parkville, VIC, Australia. 9. Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, VIC, Australia. 10. Division of Endocrinology, University of Miami, Miami, FL, USA.
Abstract
AIMS/HYPOTHESIS: Young children who develop multiple autoantibodies (mAbs) are at very high risk for type 1 diabetes. We assessed whether a population with mAbs detected by screening is also at very high risk, and how risk varies according to age, type of autoantibodies and metabolic status. METHODS: Type 1 Diabetes TrialNet Pathway to Prevention participants with mAbs (n = 1815; age, 12.35 ± 9.39 years; range, 1-49 years) were analysed. Type 1 diabetes risk was assessed according to age, autoantibody type/number (insulin autoantibodies [IAA], glutamic acid decarboxylase autoantibodies [GADA], insulinoma-associated antigen-2 autoantibodies [IA-2A] or zinc transporter 8 autoantibodies [ZnT8A]) and Index60 (composite measure of fasting C-peptide, 60 min glucose and 60 min C-peptide). Cox regression and cumulative incidence curves were utilised in this cohort study. RESULTS: Age was inversely related to type 1 diabetes risk in those with mAbs (HR 0.97 [95% CI 0.96, 0.99]). Among participants with 2 autoantibodies, those with GADA had less risk (HR 0.35 [95% CI 0.22, 0.57]) and those with IA-2A had higher risk (HR 2.82 [95% CI 1.76, 4.51]) of type 1 diabetes. Those with IAA and GADA had only a 17% 5 year risk of type 1 diabetes. The risk was significantly lower for those with Index60 <1.0 (HR 0.23 [95% CI 0.19, 0.30]) vs those with Index60 values ≥1.0. Among the 12% (225/1815) ≥12.0 years of age with GADA positivity, IA-2A negativity and Index60 <1.0, the 5 year risk of type 1 diabetes was 8%. CONCLUSIONS/ INTERPRETATION: Type 1 diabetes risk varies substantially according to age, autoantibody type and metabolic status in individuals screened for mAbs. An appreciable proportion of older children and adults with mAbs appear to have a low risk of progressing to type 1 diabetes at 5 years. With this knowledge, clinical trials of type 1 diabetes prevention can better target those most likely to progress.
AIMS/HYPOTHESIS: Young children who develop multiple autoantibodies (mAbs) are at very high risk for type 1 diabetes. We assessed whether a population with mAbs detected by screening is also at very high risk, and how risk varies according to age, type of autoantibodies and metabolic status. METHODS: Type 1 Diabetes TrialNet Pathway to Prevention participants with mAbs (n = 1815; age, 12.35 ± 9.39 years; range, 1-49 years) were analysed. Type 1 diabetes risk was assessed according to age, autoantibody type/number (insulin autoantibodies [IAA], glutamic acid decarboxylase autoantibodies [GADA], insulinoma-associated antigen-2 autoantibodies [IA-2A] or zinc transporter 8 autoantibodies [ZnT8A]) and Index60 (composite measure of fasting C-peptide, 60 min glucose and 60 min C-peptide). Cox regression and cumulative incidence curves were utilised in this cohort study. RESULTS: Age was inversely related to type 1 diabetes risk in those with mAbs (HR 0.97 [95% CI 0.96, 0.99]). Among participants with 2 autoantibodies, those with GADA had less risk (HR 0.35 [95% CI 0.22, 0.57]) and those with IA-2A had higher risk (HR 2.82 [95% CI 1.76, 4.51]) of type 1 diabetes. Those with IAA and GADA had only a 17% 5 year risk of type 1 diabetes. The risk was significantly lower for those with Index60 <1.0 (HR 0.23 [95% CI 0.19, 0.30]) vs those with Index60 values ≥1.0. Among the 12% (225/1815) ≥12.0 years of age with GADA positivity, IA-2A negativity and Index60 <1.0, the 5 year risk of type 1 diabetes was 8%. CONCLUSIONS/ INTERPRETATION:Type 1 diabetes risk varies substantially according to age, autoantibody type and metabolic status in individuals screened for mAbs. An appreciable proportion of older children and adults with mAbs appear to have a low risk of progressing to type 1 diabetes at 5 years. With this knowledge, clinical trials of type 1 diabetes prevention can better target those most likely to progress.
Entities:
Keywords:
Age; Autoantibodies; Index60; Metabolic; Type 1 diabetes
Authors: K Decochez; I H De Leeuw; B Keymeulen; C Mathieu; R Rottiers; I Weets; E Vandemeulebroucke; I Truyen; L Kaufman; F C Schuit; D G Pipeleers; F K Gorus Journal: Diabetologia Date: 2002-11-12 Impact factor: 10.122
Authors: Frans K Gorus; Eric V Balti; Anissa Messaaoui; Simke Demeester; Annelien Van Dalem; Olivier Costa; Harry Dorchy; Chantal Mathieu; Luc Van Gaal; Bart Keymeulen; Daniël G Pipeleers; Ilse Weets Journal: Diabetes Care Date: 2017-08 Impact factor: 19.112
Authors: Andrea K Steck; Alexandra Fouts; Dongmei Miao; Zhiyuan Zhao; Fran Dong; Jay Sosenko; Peter Gottlieb; Marian J Rewers; Liping Yu Journal: Diabetes Technol Ther Date: 2016-03-18 Impact factor: 6.118
Authors: Ping Xu; Yougui Wu; Yiliang Zhu; Getachew Dagne; Giffe Johnson; David Cuthbertson; Jeffrey P Krischer; Jay M Sosenko; Jay S Skyler Journal: Diabetes Care Date: 2010-08-31 Impact factor: 19.112
Authors: Liping Yu; David C Boulware; Craig A Beam; John C Hutton; Janet M Wenzlau; Carla J Greenbaum; Polly J Bingley; Jeffrey P Krischer; Jay M Sosenko; Jay S Skyler; George S Eisenbarth; Jeffrey L Mahon Journal: Diabetes Care Date: 2012-03-23 Impact factor: 19.112
Authors: Richard A Insel; Jessica L Dunne; Mark A Atkinson; Jane L Chiang; Dana Dabelea; Peter A Gottlieb; Carla J Greenbaum; Kevan C Herold; Jeffrey P Krischer; Åke Lernmark; Robert E Ratner; Marian J Rewers; Desmond A Schatz; Jay S Skyler; Jay M Sosenko; Anette-G Ziegler Journal: Diabetes Care Date: 2015-10 Impact factor: 19.112
Authors: Anna E Long; Isabel V Wilson; Dorothy J Becker; Ingrid M Libman; Vincent C Arena; F Susan Wong; Andrea K Steck; Marian J Rewers; Liping Yu; Peter Achenbach; Rosaura Casas; Johnny Ludvigsson; Alistair J K Williams; Kathleen M Gillespie Journal: Diabetologia Date: 2018-03-12 Impact factor: 10.122
Authors: Jay M Sosenko; Jay S Skyler; Jerry P Palmer; Jeffrey P Krischer; Liping Yu; Jeffrey Mahon; Craig A Beam; David C Boulware; Lisa Rafkin; Desmond Schatz; George Eisenbarth Journal: Diabetes Care Date: 2013-07-01 Impact factor: 19.112
Authors: Laura M Jacobsen; Brian N Bundy; Heba M Ismail; Mark Clements; Megan Warnock; Susan Geyer; Desmond A Schatz; Jay M Sosenko Journal: J Clin Endocrinol Metab Date: 2022-09-28 Impact factor: 6.134
Authors: William T Cefalu; Dana K Andersen; Guillermo Arreaza-Rubín; Christopher L Pin; Sheryl Sato; C Bruce Verchere; Minna Woo; Norman D Rosenblum Journal: Diabetes Care Date: 2022-01-01 Impact factor: 17.152
Authors: Andrea Lin; Jasmine A Mack; Brittany Bruggeman; Laura M Jacobsen; Amanda L Posgai; Clive H Wasserfall; Todd M Brusko; Mark A Atkinson; Stephen E Gitelman; Peter A Gottlieb; Matthew J Gurka; Clayton E Mathews; Desmond A Schatz; Michael J Haller Journal: Diabetes Date: 2021-02-25 Impact factor: 9.461
Authors: Michelle So; Colin O'Rourke; Alyssa Ylescupidez; Henry T Bahnson; Andrea K Steck; John M Wentworth; Brittany S Bruggeman; Sandra Lord; Carla J Greenbaum; Cate Speake Journal: Diabetologia Date: 2022-01-18 Impact factor: 10.122
Authors: Laura M Jacobsen; Kendra Vehik; Riitta Veijola; Katharina Warncke; Jorma Toppari; Andrea K Steck; Patricia Gesualdo; Beena Akolkar; Markus Lundgren; William A Hagopian; Jin-Xiong She; Marian Rewers; Anette-G Ziegler; Jeffrey P Krischer; Helena Elding Larsson; Michael J Haller Journal: Diabetes Care Date: 2022-03-01 Impact factor: 17.152